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Abstract
Introduction Inhibitors of cyclo-oxygenase (COX)-2 are being
extensively studied as anticancer agents. In the present study
we evaluated the mechanisms by which a highly selective COX-
2 inhibitor, celecoxib, affects tumor growth of two differentially
invasive human breast cancer cell lines.
Methods MDA-MB-231 (highly invasive) and MDA-MB-468
(moderately invasive) cell lines were treated with varying
concentrations of celecoxib in vitro, and the effects of this agent
on cell growth and angiogenesis were monitored by evaluating
cell proliferation, apoptosis, cell cycle arrest, and vasculogenic
mimicry. The in vitro results of MDA-MB-231 cell line were
further confirmed in vivo in a mouse xenograft model.
Results The highly invasive MDA-MB-231 cells express higher
levels of COX-2 than do the less invasive MDA-MB-468 cells.
Celecoxib treatment inhibited COX-2 activity, indicated by
prostaglandin E2 secretion, and caused significant growth arrest
in both breast cancer cell lines. In the highly invasive MDA-MB-
231 cells, the mechanism of celecoxib-induced growth arrest
was by induction of apoptosis, associated with reduced
activation of protein kinase B/Akt, and subsequent activation of
caspases 3 and 7. In the less invasive MDA-MB-468 cells,
growth arrest was a consequence of cell cycle arrest at the G0/
G1  checkpoint. Celecoxib-induced growth inhibition was
reversed by addition of exogenous prostaglandin E2 in MDA-
MB-468 cells but not in MDA-MB-231 cells. Furthermore, MDA-
MB-468 cells formed significantly fewer extracellular matrix
associated microvascular channels in vitro than did the high
COX-2 expressing MDA-MB-231 cells. Celecoxib treatment not
only inhibited cell growth and vascular channel formation but
also reduced vascular endothelial growth factor levels. The in
vitro findings corroborated in vivo data from a mouse xenograft
model in which daily administration of celecoxib significantly
reduced tumor growth of MDA-MB-231 cells, which was
associated with reduced vascularization and increased necrosis
in the tumor mass.
Conclusion The disparate molecular mechanisms of celecoxib-
induced growth inhibition in human breast cancer cells depends
upon the level of COX-2 expression and the invasive potential of
the cell lines examined. Data suggest a role for COX-2 not only
in the growth of cancer cells but also in activating the
angiogenic pathway through regulating levels of vascular
endothelial growth factor.
Introduction
The incidence of breast cancer – the second leading cause of
cancer death in women in the USA – is increasing, and current
therapy is unable to achieve clinical responses in patients with
highly invasive metastatic disease. There is a consequent need
for more effective approaches to prevention and treatment of
breast cancer. Nonsteroidal anti-inflammatory drugs (NSAIDs)
show great promise in this respect. Recent data on regular
NSAID use for 5–9 years indicated a 21% reduction in the
incidence of breast cancer, and regular NSAID use for 10 or
more years produced a 28% reduction in the incidence of
breast cancer [1]. Preclinical studies [2-4] have consistently
shown that NSAIDs inhibit mammary carcinogenesis.
CDK = cyclin-dependent kinase; COX = cyclo-oxygenase; DMEM = Dulbecco's modified eagle medium; DMSO = dimethyl sulfoxide; FCS = fetal 
calf serum; NSAID = nonsteroidal anti-inflammatory drug; pAkt = phosphorylated Akt; PBS = phosphate-buffered saline; PG = prostaglandin; PI = 
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Various mechanisms may be responsible for the observed
effects of NSAIDs against breast cancer. Inhibition of cyclo-
oxygenase (COX), particularly the COX-2 isozyme, and block-
ade of the prostaglandin (PG) cascade may have impacts on
neoplastic growth and development by inhibiting several key
features of mammary carcinogenesis – namely proliferation,
angiogenesis and metastasis. Inhibition of COX also causes
induction of apoptosis in malignant cells and enhances antin-
eoplastic activity of cytotoxic T lymphocytes [5-8]. Our study
conducted in newly diagnosed stage I and stage II breast can-
cer patients [9] showed impaired functionality of T cells and
dendritic cells, which correlated with COX-2 overexpression in
the tumors and increased levels of PGE2 in the serum and
tumor milieu. Therefore, a convincing case has been made for
COX-2 being an important target for the antineoplastic action
of NSAIDs. Unlike NSAIDs, COX-2 selective inhibitors such
as celecoxib and rofecoxib do not inhibit COX-1 and thus
show promise as drugs that spare the gastrointestinal system.
COX-2 is overexpressed in breast cancer tissues, and greater
extent of its expression is associated with poorer prognosis
[10]. Various environmental and nutritional risk factors induce
COX-2 expression in animal models of breast cancer [11,12].
Moreover, COX-2 selective inhibitors significantly delayed the
incidence of mammary tumors in transgenic mice expressing
the Her2/Neu, and polyoma-middle T oncogenes [13,14].
Recently, a transgenic mouse model was developed in which
the human COX-2 gene was expressed in the mammary gland
under the control of the murine mammary tumor virus promoter
[15]. That study demonstrated that enhanced COX-2 expres-
sion strongly predisposes to transformation of the mammary
gland in multiparous animals. These data strongly suggest that
local expression of COX-2 is sufficient for in situ tumor initia-
tion and/or progression. Another transgenic overexpression
study with COX-2 targeted to the epidermis also supports the
concept that COX-2 is a critical regulator of tumor progression
[16]. Transfections of the breast cancer cell line Hs578T with
cDNA for COX-2 led to an increase in expression and activity
of matrix metalloproteinase-2, resulting in increasingly invasive
behavior of the cells [17]. COX-2 specific inhibitors have the
ability to block cell growth, and induce apoptosis and cell
cycle arrest in murine mammary tumor cell lines [18]. However,
the molecular mechanisms involved are not well understood. If
COX-2 inhibitors act only by modulating COX-2 expression,
then that would imply that this therapy would be limited to
COX-2 overexpressing tumors; hence, this question is of con-
siderable clinical importance.
In the present study we established that the level of COX-2
expression and the invasive property of breast cancer cells
determines the mechanism of celecoxib-induced growth inhi-
bition; that COX-2 is involved in extracellular matrix associated
microvascular channel formation by breast cancer cells; and
that COX-2 inhibits angiogenesis in vivo. The study should fur-
ther our understanding of the cellular and molecular mecha-
nisms underlying the chemopreventive effect of a COX-2
selective inhibitor in breast cancer. To the best of our knowl-
edge, this is the first study demonstrating the diverse mode of
action of celecoxib on human breast cancer cells, which may
be dependent upon the cells' invasive properties and levels of
COX-2 expression. This is also the first report suggesting a
direct role for COX-2 in matrix associated microvascular chan-
nel formation by breast cancer cells.
Methods
Cell culture
The human breast cancer cell lines MDA-MB-231 and MDA-
MB-468 were obtained from the American Type Culture Col-
lection (ATCC; Rockville, MD, USA) and cultured following
instructions from the ATCC. Briefly, cells were grown in Dul-
becco's modified eagle medium (DMEM; GIBCO-BRL, Rock-
ville, MD, USA) supplemented with 5% fetal calf serum (FCS),
100 U penicillin, 0.1 µg streptomycin and 2 mmol/l L-glutamax.
Cells were maintained in log phase in 37°C incubator with
10% carbon dioxide. For each experiment cells were plated in
FCS-containing media in 58 cm2 culture dishes at a cell den-
sity of approximately 1 × 106 cells/dish and incubated for
another 48 hours. Cell cultures were treated with increasing
concentrations of celecoxib (20–60 µmol/l; Pfizer, New York,
NY, USA) and with dimethyl sulfoxide (DMSO; the vehicle in
which celecoxib was dissolved). The concentration of
celecoxib used in our experiments is clinically relevant
because the serum concentrations of COX-2 inhibitors in
patients range from 20 to 100 µmol/l [19]. The concentrations
used in the study are based on our titrations with celecoxib for
the two cell lines and from several published references on
other cell lines [20-22]. In both the cell lines tested there was
no evidence of apoptosis or cell cycle arrest at concentrations
below 20 µmol/l.
SDS-PAGE immunoblotting
Following harvesting of adherent cells by scraping, cell lysates
were prepared and quantified by BCA assay. Lysates (100 µg)
were resolved on a 10–15% acrylamide gel and electroblotted
onto immobilon-P polyvinylidene diflouride membranes
(Sigma, St. Louis, MO, USA). These were probed with primary
antibodies for COX-2 (p66), BAX (p23), Bcl-2 (p26), and vas-
cular endothelial growth factor (VEGF; p20), all from Santa
Cruz Biotechnology Inc. (Santa Cruz, CA, USA), and phos-
phorylated Akt (pAkt; p60; Cell Signaling, Beverly MA, USA),
and then probed with the appropriate secondary antibodies.
Bound antibodies were detected using an enhanced chemilu-
minescence detection kit (SuperSignal West Dura, Pierce,
Rockford, IL, USA), and developed on high performance
chemiluminescence films (Amersham Pharmacia Biotech, Pis-
cataway, NJ, USA).
Proliferation assay
Cell proliferation was determined by using [3H]thymidine
incorporation, in which 1 µCi of [3H]thymidine was added toAvailable online http://breast-cancer-research.com/content/7/4/R422
R424
the drug or vehicle treated cultures 16 hours before harvesting
using a Packard Cell Harvester (Packard Biosciences, Shel-
ton, CT, USA). Incorporated thymidine was evaluated using
the Topcount micro-scintillation counter (Packard Bio-
sciences). Results were expressed as [3H]thymidine uptake.
All determinations were performed in triplicate. Proliferation is
directly correlated to radioactive counts/min. In order to deter-
mine whether added PGE2 could counteract the growth inhib-
itory effect of celecoxib, we treated cells with celecoxib (40
µmol/l) and 12.5–200 pg/ml PGE2 and incubated them for 96
hours before determining [3H]thymidine incorporation, as
mentioned above.
Assay for apoptosis
Following treatment of cells with celecoxib for 48 hours, apop-
tosis was determined by staining the cells with annexin V and
propidium iodide (PI), in accordance with the manufacturer's
instructions for use of the BD Pharmingen (San Diego, CA,
USA) apoptosis kit. Briefly, an aliquot of 105 cells was incu-
bated with annexin V–fluorescein isothiocyanate and PI for 15
min at room temperature in the dark. Cells were immediately
analyzed by flow cytometry. Viable cells exclude PI and are
negative for annexin V staining, whereas early apoptotic cells
are annexin V positive and PI negative. Cells that are not viable
due to apoptotic cell death stain positive for annexin V and PI.
The percentage of stained cells in each quadrant was quanti-
fied using CellQuest software (BD Biosciences, San Jose,
CA, USA) and the total number of apoptotic cells (both early
and late apoptosis) was quantified.
Confocal microscopy for detection of apoptotic bodies
Cells were grown with celecoxib (60 µmol/l) for 48 hours and
then trypsinized. Cells were resuspended in phosphate-buff-
ered saline (PBS) with 0.1% bovine serumn albumin at a final
concentration of 5 × 107 cells/ml and 2 µl of 5 mmol/l carbox-
yfluoroscein succinimidyl ester (CFSE)/ml (Molecular Probes,
Eugene, OR, USA) was added. After 10 min of incubation at
37°C the staining was quenched by adding five times the vol-
ume of ice-cold PBS and excess stain was washed off by
repeated washes in PBS. Cells were fixed in 95% ethanol for
1 hour on ice and resuspended in PBS containing 20 µg/ml PI
(Sigma) and 15 µg/ml RNase A (Sigma). Images were cap-
tured on the LSM510 confocal microscope (Carl Zeiss Inc.,
Gottingen, Germany) using excitation wavelengths of 488 nm
(for CFSE) and 543 nm (for PI).
Assay for caspases 3 and 7
To evaluate whether celecoxib treatment can induce activation
of caspases 3 and 7, we detected levels of active forms of cas-
pases 3 and 7 in cell lysates from treated and untreated cells
using the EnzChek Caspase-3/7 Assay Kit (Molecular
Probes), in accordance with the manufacturer's protocol. In
principle, active caspase 3 or 7 cleaves a fluorogenic sub-
strate; this releases the fluorochrome, which is detected using
a spectrofluorometer.
Cell cycle analysis
Cells were treated with increasing concentrations (20–60
µmol/l) of celecoxib or DMSO (vehicle) in medium supple-
mented with 5% FCS for 48 hours. The adherent and the non-
adherent cell fractions were harvested and cell pellets were
fixed and permeabilized in 95% cold ethanol, and resus-
pended in PBS containing 20 µg/ml PI (Sigma) and 15 µg/ml
RNase A (Sigma). Samples were incubated in the dark at
37°C for 30 min and analyzed by flow cytometry (Becton Dick-
inson, San Diego, CA, USA). For each sample, 50,000 fluores-
cent cells were counted. Data were analyzed using the ModFit
software (Verity Software House Inc., Topsham, ME, USA) to
determine DNA content and cell cycle phase (G0/G1–S–G2/
M phase). Cell doublets and clumps were eliminated from the
analyses by gating.
Prostaglandin E2 production
Cells were treated with increasing concentrations (20–60
µmol/l) celecoxib or DMSO (vehicle) in medium supplemented
with 5% FCS for 48 hours. Levels of PGE2 released in media
were measured using a PGE2 enzyme immunoassay kit from
Cayman Chemical Co. (Ann Arbor, MI, USA). Medium was
sampled, centrifuged to remove floating cells and frozen imme-
diately at -70°C until assay. The PGE2 assay was performed in
accordance with the manufacturer's instructions, following
dilution to ensure that readings were within the limits of accu-
rate detection by the assay. The results are expressed as pg
PGE2/ml ± standard deviation.
Assay for vasculogenic mimicry
This assay was performed as described [23]. Cells were
grown until they were about 80% confluent. The growth
medium was replaced with serum-free DMEM supplemented
with 100 µg/ml heparin (Elkins-Sinn, Inc. Cherry Hill, NJ, USA)
and antibiotics, and cells were incubated for 24 additional
hours. The cells were trypsinized, counted, and resuspended
in media (at a concentration of 4 × 104 cells/ml) containing 40
and 60 µmol/l concentrations of celecoxib or vehicle. The
wells of a 24-well tissue culture plate were evenly coated with
0.1 ml/well growth factor reduced Matrigel (BD Biosciences),
which was allowed to solidify at 37°C for 30 min, in accord-
ance with the manufacturer's instructions, before the cells
were plated. The cell suspension was plated (1 ml/well) onto
the surface of Matrigel and incubated at 37°C for 48 hours
and photographed using a Nikon inverted phase contrast pho-
tomicroscope (Nikon USA, Garden City, NY, USA). Channel
formation was quantified as percentage of channels formed by
counting the number of connected cells in five randomly
selected fields, using 200× magnification, and dividing the
number by the total number of cells in the same field.
Xenografts
Male athymic nude mice (age 6–8 weeks) were obtained from
NxGen Biosciences Inc. (San Diego, CA, USA) and animals
were housed under specific pathogen-free conditions. FiveBreast Cancer Research    Vol 7 No 4    Basu et al.
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mice/group were prophylactically treated with either celecoxib
(25 mg/kg body weight) or vehicle DMSO for 7 days before
the tumor cells were inoculated. MDA-MB-231 cells were har-
vested by centrifugation and 5 × 106 cells were suspended in
150 µl of serum free DMEM with an equal volume of cold liquid
Matrigel (10 mg/ml). The suspension was injected subcutane-
ously in the mice. In order to determine the optimal cell number
to be injected, titration with varying cell numbers was done on
nude mice and the tumorigenicity of the cell line determined.
The growth of these tumors was monitored by weekly exami-
nation, and growth rates were determined using caliper meas-
urements. Tumor weight was calculated according to the
following equation [24]: tumor weight (g) = (length (cm) ×
width (cm)2) × 0.5. Experiments were terminated 45 days after
tumor cell injection. It was necessary to kill some of the mice
earlier because of the aggressive nature of the tumor.
Histologic studies
All solid tumors resulting were excised and fixed in formalde-
hyde, and paraffin-embedded blocks was sectioned at a thick-
ness of 7 µm. Histologic evaluation of vascularity was
determined by Masson's trichrome staining [25]. This method
stains fibrous tissue and stroma green. Blood vessels contain-
ing red blood cells stain bright red. Immunohistochemical
localization of factor VIII related antigen on endothelial cells
was determined using the polyclonal rabbit antihuman von
Willebrand factor purchased from Dako Cytomation (Glos-
trup, Denmark), using the manufacturer's recommended stain-
ing protocol.
Statistical analysis
The celecoxib experiments were run in triplicate; the mean as
well as standard deviations were computed. The means were
then compared using one-way analysis of variance with Dun-
nett adjustment.
Results
Cyclo-oxygenase-2 protein is differentially expressed in 
breast cancer cell lines
We studied two human breast cancer cell lines, MDA-MB-231
and MDA-MB-468, for COX-2 expression by western blotting.
Both cell lines expressed COX-2, although MDA-MB-468
cells exhibited lower protein expression than did MDA-MB-
231 cells. Western blot analysis for COX-2 protein in the
MDA-MB-231 cell line showed little change in protein expres-
sion after treatment with 20–40 µmol/l celecoxib. At the level
of 60 µmol/l there was a slight increase in COX-2 expression.
However, in the MDA-MB-468 cell line there was significant
downregulation of COX-2 expression upon drug treatment
(Fig. 1a).
Celecoxib inhibits growth and proliferation of breast 
cancer cell lines
Celecoxib at concentrations of 20, 40, and 60 µmol/l was
used to treat the two cell lines for 48 hours. Under the phase
contrast microscope, both cell lines exhibited a dramatic mor-
phologic change as well as growth arrest after 48 hours of
drug treatment (data not shown). The rate of proliferation in
response to celecoxib treatment was assayed by measuring
incorporation of [3H]thymidine uptake. Significant inhibition of
proliferation was observed in both cell lines in a dose-depend-
ent manner, in response to varying concentrations of celecoxib
at 96 hours after treatment (P  < 0.001; Fig. 1b). Similar
growth inhibition was observed at earlier time points (48 and
72 hours after treatment (data not shown).
Celecoxib induces apoptosis in MDA-MB-231 but not in 
MDA-MB-468 cells
Because COX inhibitors have been reported to mediate apop-
tosis in many cells [26,27], we investigated whether the
observed growth inhibition mediated by celecoxib was associ-
ated with induction of programmed cell death. Flow cytometric
analysis of annexin V/PI staining in celecoxib-treated and vehi-
cle-treated cells was used to analyze apoptosis. Following 48
hours of drug treatment, induction of apoptosis was observed
in the MDA-MB-231 cells in a dose-dependent manner (Fig.
2a). Celecoxib at concentrations of 40 and 60 µmol/l caused
significant increases in the percentage apoptotic cells (P =
0.01 and P < 0.001, respectively). In the MDA-MB-468 cell
line apoptosis was not induced with celecoxib treatment (Fig.
2a). In spite of the lack of evidence of increased apoptosis,
MDA-MB-468 cells had significantly lower proliferation after
drug treatment (Fig. 1b). Treated cells appeared rounded up
and exhibited atypical morphology (data not shown), which
suggested that alterations in the adhesive properties of these
cells might have occurred and other pathways may be involved
in the growth inhibition observed in MDA-MB-468 cells.
Celecoxib induces formation of apoptotic bodies and 
loss of nuclear envelope integrity in MDA-MB-231 cells
To follow up on the celecoxib-induced apoptosis of the MDA-
MB-231 cells, we analyzed morphological changes in MDA-
MB-231 cells after celecoxib treatment using confocal micro-
scopy. Celecoxib at concentrations of 40 and 60 µmol/l
caused loss of integrity of nuclear envelope and induced for-
mation of peripheral, sharply delineated masses of condensed
chromatin or apoptotic bodies, which are characteristic struc-
tural features of apoptosis (Fig. 2b–e). Membrane blebbing
was also observed, along with loss of plasma membrane integ-
rity in some cells (data not shown). These results indicate that
celecoxib treatment caused architectural changes in mem-
brane and cell nucleus within 48 hours of treatment. No such
changes were observed in MDA-MB-468 cells (data not
shown), which correlated with our observation that there was
no significant induction of apoptosis in these cells after
celecoxib treatment (Fig. 2a).Available online http://breast-cancer-research.com/content/7/4/R422
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Celecoxib inhibits activation of protein kinase B/Akt 
kinase in MDA-MB-231 cells
Protein kinase B, Akt, is a serine/threonine protein kinase that
is involved in promoting cell survival signals through the phos-
phoinositide 3-kinase pathway, leading to inactivation of a
series of proapoptotic proteins. Akt also represents a key sig-
naling component in cell survival by mediating the activation of
downstream effectors such as BAD [28,29] and procaspase-
9 [30]. Celecoxib was recently shown to induce apoptosis of
cancer cells by blocking Akt activation in rat cholangiocarci-
noma and human prostate cancer cells in vitro [21,22]. To
explore whether inhibition of Akt activation may be the mecha-
nism responsible for induction of apoptosis in MDA-MB-231
cells, we determined the effect of celecoxib on phosphoryla-
tion of Akt on breast cancer cell lines. Breast cancer cells were
exposed to varying doses of celecoxib for 48 hours, and Akt
and pAkt in cell lysates were determined by western blot anal-
ysis. At a concentration of 20 µmol/l, celecoxib caused slight
increase in pAkt in MDA-MB-231 cells. At a concentration of
60 µmol/l, celecoxib treatment significantly (P = 0.002) down-
regulated the level of phosphorylation of Akt in MDA-MB-231
cells but not in MDA-MB-468 cells (Fig. 3a,b), suggesting that
the mechanism of apoptosis induction in MDA-MB-231 cells
was, in part, dependent upon decreased phosphorylation of
Akt protein. Because Akt represents a key signaling compo-
nent in cell survival by activating downstream apoptotic pro-
teins [28-31], we evaluated the levels of Bax and Bcl-2 by
western blot analysis of lysates derived from both cell lines
Figure 1
Celecoxib regulates COX-2 levels and causes growth arrest in human breast cancer cells Celecoxib regulates COX-2 levels and causes growth arrest in human breast cancer cells. (a) Cyclo-oxygenase (COX)-2 is expressed in both MDA-
MB-231 and MDA-MB-468 cell lines. Western blot analysis of vehicle and celecoxib (20–60 µmol/l) treated cells. SDS-PAGE electrophoresis was 
performed using a 10% resolving gel. Protein was loaded at 100 µg per lane. Lipopolysaccharide/phorbol 12-myristate 13-acetate treated whole 
cell lysate from RAW264.7 cell line was used as positive control. Gels were blotted and probed with COX-2 monoclonal antibody. Both cell lines 
expressed COX-2. MDA-MB-231 cells expressed higher levels of COX-2 than did MDA-MB-468 cells. With drug treatment, COX-2 protein level did 
not change in the MDA-MB-231 cells, but there was reduction in the level of COX-2 protein in the MDA-MB-468 cells after treatment. β -Actin blot is 
included to confirm equal loading. These experiments were repeated three times with similar results. (b) Celecoxib induced dose-dependent inhibi-
tion of proliferation of breast cancer cell lines. Cells were incubated for 4 days with vehicle or celecoxib, and [3H]thymidine was added 24 hours 
before harvest. After washing off excess thymidine, cells were lysed with 5% Triton X-100, and incorporated thymidine was evaluated. Celecoxib 
treatment caused significant dose-dependent growth inhibition in both human breast cancer cell lines. Mean values of three experiments ± standard 
deviation is shown. P values represent significant differences between vehicle control and celecoxib treatment.Breast Cancer Research    Vol 7 No 4    Basu et al.
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after celecoxib treatment. Treatment with celecoxib at concen-
trations of 40 and 60 µmol/l induced increased expression of
Bax in the MDA-MB-231 cells (Fig. 3c), but no significant
decrease in Bcl-2 was observed (data not shown). In MDA-
MB-468 cells, in which apoptosis was not evident, levels of
pAkt and Bax remained unchanged with treatment (Fig. 3a,b).
Celecoxib induces caspase-3/7 activation in MDA-MB-
231 cells
Caspases are responsible for many of the biochemical and
morphological changes that occur during apoptosis. Most
apoptotic signals induce intracellular cleavage of caspases 3
and 7 from an inactive precursor (p32–p35) to the active
forms (p17 and p12); hence, these proteins are the most
extensively studied apoptotic proteins. The effector caspases
3 and 7 proteolytically cleave and activate several other cas-
pases as well as several other apoptotic proteins, including
the DNA fragmentation protein poly-ADP-ribose polymerase
(PARP), which is one of the primary activators of DNA frag-
mentation and cell death [32-34].
We investigated whether celecoxib induced the activation of
caspase 3 and caspase 7 in MDA-MB-231 cells in which
apoptosis was induced. Caspase activity is presented as fluo-
rescence emission, which is directly proportional to activities
of caspases 3 and 7. Treatment with celecoxib (40 and 60
µmol/l) for 48 hours caused significant increases in activation
of caspases 3 and 7 (fivefold increase at the 40 µmol/l con-
centration [P = 0.008] and sixfold increase at the 60 µmol/l
concentration [P = 0.002]; Fig. 3d). Caspase activation was
completely blocked by incubation with the caspase inhibitor
Ac-DEVD-CHO (data not shown). These results suggest that
celecoxib-induced apoptosis in MDA-MB-231 cells is due to
activation of caspases 3 and 7, which is corroborated by stud-
ies indicating that the blockade or absence of caspase activa-
tion is sufficient to inhibit effective apoptosis [35]. In contrast,
caspase activation was not observed in celecoxib-treated
MDA-MB-468 cells, which correlated with no significant
increase in apoptosis with celecoxib treatment (Fig. 2).
Celecoxib induces cell cycle arrest at the G0/G1 
checkpoint in MDA-MB-468 but not in MDA-MB-231 cells
To determine whether celecoxib-induced growth inhibition
was due to changes in cell cycle progression, flow cytometric
analysis was performed on cells treated with increasing con-
centrations of celecoxib (20–60 µmol/l) for 48 hours. In MDA-
MB-468 cells, in which celecoxib did not induce apoptosis,
there was induction of cell cycle arrest. At 40 and 60 µmol/l
concentrations of celecoxib, significant increases (P = 0.02
and P < 0.001, respectively) in the proportion of cells that
Figure 2
Celecoxib induces apoptosis in MDA-MB-231 cells Celecoxib induces apoptosis in MDA-MB-231 cells. (a) Flow cytometric analysis of vehicle-treated and celecoxib-treated cells stained with annexin 
V and propidium iodide (PI) was done 48 hours after treatment. The population shown in the figure is total apoptotic cells, which includes early and 
late apoptosis. Significant induction of apoptosis was observed in the MDA-MB-231 cells at 40 and 60 µmol/l concentrations of celecoxib. Apopto-
sis was not induced in MDA-MB-468 cells. Mean values of three experiments ± standard deviation is shown. P values represent significant differ-
ences between vehicle control and celecoxib treatment. (b–e) Celecoxib induces formation of apoptotic bodies in MDA-MB-231 cells. Shown are 
confocal images of MDA-MB-231 cells subjected to 48 hours of celecoxib (60 µmol/l) treatment. Cells were stained with CFSE (panel d) and then 
fixed in 95% ethanol and stained with PI (panel c). Cells were visualized in a confocal microscope (Carl Zeiss Inc.) using excitation wavelengths of 
488 nm (for CFSE) and 543 nm (for PI). Loss of integrity of nuclear envelope and formation of peripheral, sharply delineated masses of condensed 
chromatin or apoptotic bodies are visualized. Panel b represents phase contrast images of the cells and panel e represents colocalization of CFSE 
and PI. Images were taken 200×.Available online http://breast-cancer-research.com/content/7/4/R422
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were arrested at the G0/G1 checkpoint of the cell cycle were
observed. Subsequently, significant inhibition of transition to
the G2/M phase (P = 0.02 at 60 µmol/l) and S phase (P =
0.006 and P < 0.001 at 40 and 60 µmol/l) was observed (Fig.
4b). Thus, growth inhibitory activity of celecoxib on these
MDA-MB-468 cells was due to cell cycle arrest at G0/G1
phase and not due to induction of apoptosis. The cell cycle
arrest persisted at 72 hours after drug treatment (data not
shown). In MDA-MB-231 cells there was no significant differ-
ence in cell cycle progression with celecoxib treatment for 48
hours (Fig. 4a).
Celecoxib inhibits cyclo-oxygenase-2 induced 
prostaglandin E2 production in both cell lines
COX-2 converts arachidonic acid to bioactive prostanoids. It
has been demonstrated that COX-2 derived PGE2 is the major
Figure 3
Celecoxib induced down-regulation of pAkt, increase in Bax, and cas- pase 3/7 in MDA-MB-231 cells Celecoxib induced down-regulation of pAkt, increase in Bax, and cas-
pase 3/7 in MDA-MB-231 cells. (a) Total Akt and phosphorylated Akt 
(pAkt). Western blot analysis of cell lysates prepared from vehicle and 
celecoxib (20–60 µmol/l) treated cells. SDS-PAGE electrophoresis 
was performed using 10% resolving gel. Protein was loaded at 100 µg 
per lane and the protein of interest was detected using specific anti-
bodies. Celecoxib treatment at 40 and 60 µmol/l caused decreases in 
the levels of pAkt in MDA-MB-231 cells, with no change in MDA-MB-
468 cells. Numbers below each lane represents percentage of protein 
expression compared with vehicle-treated cell lysate, which was set to 
equivalent to 100%, as determined by densitometric analysis. Control 
cell extracts from Jurkats were used as positive control for Akt and 
pAkt. (b) Average densitometric values of three separate experiments 
showing reduction in pAkt with celecoxib treatment. There was a signif-
icant decrease (P = 0.002) in the levels of pAkt with 60 µmol/l 
celecoxib treatment. (c) Western blot analysis of BAX. Increased 
expression of BAX protein was observed with increasing concentra-
tions of celecoxib in MDA-MB-231 cells but not in MDA-MB-468 cells. 
The experiment was repeated three times with similar results. A β -actin 
blot is included to show equal loading. (d) Spectrofluorometric analysis 
of lysates prepared from vehicle and celecoxib (20–60 µmol/l) treated 
cells at 48 hours. Activity of caspases 3 and 7 was monitored by enzy-
matic cleavage using a fluorescence microplate reader with excitation 
at 485 ± 10 nm and emission detection at 530 ± 12.5 nm. In MDA-MB-
231 cells, activities of caspases 3 and 7 were increased significantly at 
40 µmol/l and 60 µmol/l drug concentrations. No increase in caspase 
activity was evident in the MDA-MB-468 cells. Mean values from three 
experiments ± standard deviation is shown. P values represent signifi-
cant differences between vehicle control and celecoxib treatment.
Figure 4
Celecoxib causes cell cycle arrest in MDA-MB-468 cells Celecoxib causes cell cycle arrest in MDA-MB-468 cells. (a,b) Flow 
cytometric analysis of cells subjected to treatment with vehicle or 
celecoxib (20–60 µmol/l) for 48 hours. Cells were fixed and permeabi-
lized with 95% ethanol, stained with propidium iodide, and analyzed by 
flow cytometry. Celecoxib induced growth arrest at the G0/G1 cell cycle 
checkpoint in MDA-MB-468 cells (panel b) with no cell cycle arrest in 
the MDA-MB-231 cells (panel a). Mean values for three experiments ± 
standard deviation of the mean is shown. P values represent significant 
difference between vehicle control and celecoxib treatment. Experi-
ments were repeated three times, with similar results.Breast Cancer Research    Vol 7 No 4    Basu et al.
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prostaglandin produced by breast cancer cells [36]. To
determine whether COX-2 activity was affected by celecoxib
treatment, PGE2 production using a PGE2-specific enzyme-
linked immunosorbent assay was measured in conditioned
medium collected from the breast cancer cell lines after
celecoxib-treatment (20–60 µmol/l) for 48 hours. All doses of
celecoxib significantly reduced PGE2 secretion by both cell
lines (P < 0.01 for MDA-MB-231 and P = 0.03, 0.02 and 0.01
for MDA-MB-468 cells; Table 1), indicating that celecoxib is a
potent inhibitor of COX-2 induced PGE2 production.
Celecoxib-induced growth inhibition is reversed by 
exogenous prostaglandin E2 only in MDA-MB-468 cells
Because celecoxib caused growth inhibition in the two breast
cancer cell lines and inhibited PGE2 secretion, we hypothe-
sized that this growth inhibition was PGE2 dependent. To
determine whether celecoxib-induced growth inhibition could
be reversed by exogenous PGE2, PGE2 was added to cultures
of MDA-MB-231 and MDA-MB-468 cells treated with con-
stant dose (40 µmol/l) of celecoxib. Varying amounts of PGE2
(12.5–200 pg/ml) were added to the medium in order to take
into account the fact that some of the PGE2 may degrade or
be internalized into cells. In MDA-MB-231 cells, growth inhibi-
tion induced by 40 µmol/l celecoxib could not be restored by
addition of exogenous PGE2 (Fig. 5a), thereby suggesting that
celecoxib-induced growth inhibition in MDA-MB-231 cells
may be independent of PGE2 levels. However, addition of 200
pg/ml PGE2 completely reversed the growth inhibition induced
by 40 µmol/l celecoxib in the less invasive MDA-MB-468 cells
(Fig. 5b), suggesting that celecoxib-induced growth regulation
of these cell lines may be dependent on the levels of PGE2.
Celecoxib inhibits in vitro matrix-associated vascular 
channel formation
Recent findings demonstrate the unusual ability of aggressive
human breast cancer cells to form tubular structures in three-
dimensional Matrigel cultures. The generation of these chan-
nels by epithelial tumor cells is called vascular mimicry [37-
39]. One study [40] suggested a connection between angio-
genesis and formation of these channels. Because celecoxib
is known to act as an inhibitor of angiogenesis, we
investigated the ability of MDA-MB-231 and MDA-MB-468
cells to form the microvascular channels with and without
celecoxib treatment. MDA-MB-231 cells, which express ele-
vated levels of COX-2 and are highly invasive, begin to form
tubular structures in under 16 hours when plated on Matrigel
(data not shown) and form very characterized microvascular
channels by 48 hours. In contrast, MDA-MB-468 cells, which
have lower COX-2 and are less invasive, start tubule formation
much later, at approximately 30 hours, and exhibit significantly
fewer microvascular channels at 48 hours than do MDA-MB-
231 cells. These observations were specific for the high or
moderately invasive cells, because the noninvasive breast can-
cer cells (ZR-75-1) did not form channels in vitro under iden-
tical culture conditions (data not shown).
We found that celecoxib treatment at concentrations of 40
and 60 µmol/l was able to reduce significantly the formation of
channels in both breast cancer cell lines in a dose-dependent
manner, as compared with vehicle treated cells (P < 0.001 for
MDA-MB-231 cells and P < 0.001 for MDA-MB-468 cells;
Fig. 6a), suggesting a role for COX-2 in channel formation. The
effect of celecoxib on channel formation was only quantified
on live adherent cells in Matrigel as the apoptosed and dead
cells float into the media. Thus, we believe that the negative
effect of celecoxib on channel formation was not due to cell
death, which was also measured by trypan blue exclusion
(data not shown).
Celecoxib inhibits expression of vascular endothelial 
growth factor protein in MDA-MB-231 cells
Recent reports have shown that a nonspecific COX inhibitor
(indomethacin) suppresses the expression of VEGF gene
expression in vitro in mammary tumor cells [41]. We evaluated
the levels of VEGF protein from tumor lysate of cells treated
with vehicle or increasing doses of celecoxib. Compared with
control, celecoxib (20–60 µmol/l) treatment reduced expres-
sion of VEGF in the MDA-MB-231 cells in a dose-dependent
manner (Fig. 6b). No such reduction was observed in the
MDA-MB-468 cells treated with celecoxib (Fig. 6b), suggest-
ing that in the highly aggressive MDA-MB-231 cells the COX-
2/PGE2 pathway may play a critical role in channel formation
Table 1
Celecoxib inhibited prostaglandin E2 secretion by breast cancer cells
Treatment MDA-MB-231 P value MDA-MB-468 P value
Vehicle 430.0 ± 178.2 76.6 ± 15.2
Celecoxib 20 µmol/l 30.1 ± 2.9 <0.01 39.0 ± 16.5 0.03
Celecoxib 40 µmol/l 30.7 ± 4.7 <0.01 37.3 ± 11.0 0.02
Celecoxib 60 µmol/l 37.7 ± 13.6 <0.01 30.3 ± 13.6 0.01
Forty-eight hours post treatment, conditioned medium from vehicle and celecoxib (20–60 µmol/l) treated cells were harvested and prostaglandin 
(PG)E2 levels (pg/ml) determined by enzyme-linked immunosorbent assay. In all cell lines, PGE2 levels were significantly reduced at all doses of 
celecoxib. The experiment was repeated three times and in triplicate. P values represent significant differences between vehicle control and 
celecoxib treatment.Available online http://breast-cancer-research.com/content/7/4/R422
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and angiogenesis, in part by activating proangiogenic proteins
such as VEGF. Future studies will evaluate other proteins
associated with the angiogenic pathway.
In vivo tumor growth was reduced with celecoxib 
treatment
Nude mice were prophylactically treated with celecoxib or
vehicle for 1 week before tumor challenge with MDA-MB-231
cells in Matrigel. Celecoxib treatment was continued for 45
days after tumor challenge. Mice treated with celecoxib (25
mg/kg body weight) exhibited significant (P = 0.01) reduction
in tumor growth as compared with vehicle-treated mice with-
out evidence of systemic toxicity (Fig. 7a). A representative
mouse from each treatment group is shown in Fig. 7b; the
treated mouse has reduced tumor mass compared with the
control mouse.
In vivo inhibition of angiogenesis and increase in 
necrosis with celecoxib treatment
Vascularity of tumor implants was histologically evaluated
using Masson's trichrome and factor VIII-related antigen stain-
ing. Tumors from celecoxib-treated mice showed reduced
blood vessels as compared with tumors excised from vehicle-
treated mice (Fig. 8). Furthermore, there was evidence of
necrosis in the celecoxib-treated tumors relative to those
obtained from vehicle-treated animals (Fig. 8a,b).
Discussion
The results presented here clearly show that celecoxib
strongly suppresses cell growth and proliferation in both
human breast cancer cell lines (Fig. 1b). However, the mech-
anism of antitumor effect is dependent upon COX-2
expression and the invasive properties of the cancer cell. The
highly invasive MDA-MB-231 cells undergo induction of apop-
tosis (Fig. 2) and the less invasive MDA-MB-468 cells undergo
cell cycle arrest (Fig. 4) after treatment with celecoxib. The two
cell lines exhibit different levels of COX-2 protein expression,
with MDA-MB-231 cells expressing much higher levels than
MDA-MB-468 cells (Fig. 1a), which directly correlated with the
amount of PGE2 production by the cells (Table 1) and their
invasive properties. Our data are in good agreement with the
postulate that elevated production of COX-2-induced
prostanoids is a hallmark of highly metastasizing breast cancer
cells [41,42]. The two cell lines regulate COX-2 protein differ-
ently after celecoxib treatment, with downregulation of the pro-
tein observed in MDA-MB-468 cells but not in MDA-MB-231
cells (Fig. 1a). In fact there was an increase in COX-2 expres-
sion in MDA-MB-231 cells at the 60 µmol/l level of celecoxib,
the mechanism for which is not known. However, one or more
COX-produced products may repress COX expression in a
negative feedback loop. Removal of negative feedback by
celecoxib treatment would result in COX-2 induction. There
are similar reports on celecoxib treatment leading to strong
upregulation of COX-2 protein expression in 184htert breast
cancer cells [43].
Regardless of COX-2 expression and regulation patterns,
celecoxib treatment reduced PGE2 secretion by both cell lines
(Table 1), but provision of exogenous PGE2  reversed
celecoxib-induced growth inhibition in the MDA-MB-468 cells
only, and not in the MDA-MB-231 cells (Fig. 5). This suggests
that celecoxib-induced growth inhibition of the highly
aggressive MDA-MB-231 cells is independent of PGE2. Cor-
roborating our findings are previous reports that growth inhibi-
tion induced by COX-2 inhibitors in some carcinoma cell lines
can be completely abrogated by exogenous addition of PGE2
[44], whereas in other studies addition of PGE2 had no effect
[45,46]. One possible PGE2-independent mechanism by
which celecoxib may have caused apoptosis in MDA-MB-231
Figure 5
Growth inhibition of MDA-MB-468 cells was abrogated by exogenous  prostaglandin (PG)E2 addition Growth inhibition of MDA-MB-468 cells was abrogated by exogenous 
prostaglandin (PG)E2 addition. [3H]thymidine uptake assay was done to 
determine proliferation of (a) MDA-MB-231 and (b) MDA-MB-468 cells 
treated with 40 µmol/l celecoxib with or without varying amounts of 
exogenous PGE2 (12.5–200 pg/ml). Cells were harvested after 96 
hours in culture. In MDA-MB-231 cells, growth inhibition induced by 40 
µmol/l celecoxib could not be restored by addition of exogenous PGE2; 
however, addition of 200 pg/ml PGE2 completely reversed the growth 
inhibition induced by 40 µmol/l celecoxib in the less invasive MDA-MB-
468 cells. Average values of three experiments ± standard deviation is 
shown. P values represent significant differences between vehicle con-
trol and celecoxib treatment.Breast Cancer Research    Vol 7 No 4    Basu et al.
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cell lines could be through the accumulation of the prostaglan-
din precursor arachidonic acid. Arachidonic acid is known to
be converted to an intermediate, apoptosis-signaling com-
pound, namely ceramide, which causes NSAID-induced apop-
tosis in cancer cells [47]. This phenomenon of ceramide-
induced apoptosis has been proven in a murine mammary
tumor cell line treated with celecoxib [18]. Because PGE2 is
the major prostanoid released from breast cancer cells [41],
we focused our studies on PGE2 levels. However, a possible
role of other prostanoids such as PGD2, PGI, PGF2α  and
thromboxane2 cannot be ruled out, and future studies will
include analyses of other prostanoids.
Thus, we observed that the mechanisms driving celecoxib-
induced growth inhibition are very diverse in the two cells
lines, depending upon COX-2 expression levels, invasive
properties, and dependence on PGE2. At the cellular level,
celecoxib induced the characteristic features of apoptosis in
the MDA-MB-231 cells (Fig. 2). At the molecular level, activa-
tion of protein kinase B/Akt was significantly reduced at 60
µmol/l concentration of celecoxib, with increased activation of
proapoptotic protein Bax and caspases 3 and 7 (Fig. 3). These
results are in agreement with those of other studies in which it
was suggested that activation of effector caspases 3 and 7
and Bax proteins, downstream of phosphoinositide 3-kinase/
Akt inactivation, was the mechanism of celecoxib-induced
tumor cell apoptosis [22,48]. Mechanisms leading to the
downregulation of Akt activation are not clear. It has been sug-
gested that inhibition of the tumor suppressor PTEN, a
phosphatase that targets phosphoinositol triphosphate, or
inhibition of 3-phosphoinositide-dependent kinase 1 activity
may be involved [48-50].
In contrast to MDA-MB-231 cells, growth of MDA-MB-468
cells was inhibited by induction of cell cycle arrest at the G0/
G1 phase of the cell cycle (Fig. 4). Similar cell cycle arrest has
been reported using a murine mammary tumor cell line derived
from a spontaneously occurring tumor [18], human pancreatic
cancer cell lines [51], and human ovarian cancer cell lines
[52]. It is not clear from our studies that celecoxib directly
affects cell cycle distribution by regulating cyclin D1 levels,
which is one of the major cyclins known to be upregulated
during cancer. Preliminary data evaluating cyclin D1 levels in
MDA-MB-468 cells after celecoxib treatment were inconclu-
sive (data not shown) and more thorough analysis is needed.
The question remains whether COX-2 induced PGE2 can
directly regulate cyclin D1 or other network of cyclins, cyclin-
dependent kinases (CDKs) or CDK inhibitors. For other cell
types, including colon, lung and squamous cell carcinomas, it
has been reported that treatment with NSAIDs results in
upregulation of CDK inhibitors that regulate accumulation of
cells in G0/G1 [53-55]. In breast cancer cells, this remains to
be examined.
Angiogenesis plays a crucial role in tumor development and
progression. COX-2 dependent PGE2 production represents
a likely candidate for the angiogenic response observed in
several tumors, including mammary tumors [36,56-58]. To
explore the role played by COX-2 inhibitors in angiogenesis,
we used both in vitro and in vivo model systems. Aggressive
breast epithelial cells are known to differentiate into tubules
when cultured on growth factor reduced Matrigel. This phe-
nomenon is known as vasculogenic mimicry. Its presence has
been reported in inflammatory breast cancer patients and is
associated with reduced 5-year survival and higher percent-
age of recurrence [59]. Shirakawa and coworkers [40] sug-
gested a connection between vascular mimicry and
angiogenesis, based on the existence of blood flow in the vas-
cular channels. When plated on growth factor reduced
Matrigel, human breast cancer cell lines have the unique ability
to form tubular channels. We showed that the more aggres-
sive MDA-MB-231 cells generate channels more efficiently
and in higher numbers than do the less aggressive MDA-MB-
Figure 6
Celecoxib treatment causes reduction in microvascular channel forma- tion by regulating VEGF levels Celecoxib treatment causes reduction in microvascular channel forma-
tion by regulating VEGF levels. (a) The percentage of cells forming 
channels was much greater in MDA-MB-231 cells than in MDA-MB-
468 cells. In both cells, treatment with 40 and 60 µmol/l celecoxib 
caused significant reduction in the number of channels. P values repre-
sent significant differences between vehicle control and celecoxib treat-
ment. (b) Western blot analysis of cell lysates prepared from vehicle 
and celecoxib (20–60 µmol/l) treated cells. SDS-PAGE electrophore-
sis was performed using 15% resolving gel. Protein was loaded at 100 
µg per lane and the protein was detected using vascular endothelial 
growth factor (VEGF) antibody. Celecoxib treatment decreased VEGF 
levels in MDA-MB-231 cells in a dose-dependent manner.Available online http://breast-cancer-research.com/content/7/4/R422
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468 cell line (Fig. 6a). Similarly, it was shown that highly
aggressive melanoma cells, when seeded on three-dimen-
sional matrices of collagen I, form extracellular matrix-rich pat-
terned networks that surround clusters of tumor cells;
however, under the same culture conditions, poorly aggressive
melanoma cells did not form the patterned networks [38].
When treated with increasing concentrations of celecoxib
(40–60 µmol/l) we observed a dose-dependent decrease in
the ability of both cell lines to differentiate into channels (Fig.
6a). Our findings are in accordance with those of other
reports, in which capillary-like tube formation by human umbil-
ical vein endothelial cells cocultured with COX-2 overexpress-
Figure 7
Celecoxib treatment reduced MDA-MB-231 tumor growth in nude mice Celecoxib treatment reduced MDA-MB-231 tumor growth in nude 
mice. (a) Five mice per group were treated with either celecoxib (25 
mg/kg body weight) or vehicle (dimethyl sulfoxide) and the mice were 
killed 45 days after the tumor cells were inoculated. Tumor growth was 
monitored by weekly examination using digital calipers, and tumor 
weight was calculated using to the following equation [23]: tumor 
weight (g) = (length (cm) × width (cm)2) × 0.5. Three mice from the 
vehicle-treated group had to be killed early because of the aggressive 
nature of the tumor. The other two mice in the vehicle-treated group 
had significantly greater tumor burden (P = 0.01) than did the five mice 
in celecoxib-treated group. (b) A representative mouse from each treat-
ment group is illustrated; lower tumor mass Is evident in the treated ani-
mal as compared with the vehicle control.
Figure 8
In vivo inhibition of angiogenesis and increase in necrosis with  celecoxib treatment In vivo inhibition of angiogenesis and increase in necrosis with 
celecoxib treatment. Vascularity of tumor implants was histologically 
evaluated by Masson's trichrome and factor VIII related antigen stain-
ing. Shown is evidence of central necrosis and decreased number of 
blood vessels in (b) a section of celecoxib-treated tumors relative to (a) 
a section obtained from a vehicle-treated animal (magnification 50×). 
Greater magnification (100×) of (c) panel a and (d) panel b are shown 
in the next two panels. Arrows in panel c point to blood vessels. 
Endothelial cells lining the blood vessels stained positively for factor VIII 
related antigen and showed larger blood vessels in the (e) vehicle-
treated than in the (f) celecoxib-treated samples (magnification 100×).Breast Cancer Research    Vol 7 No 4    Basu et al.
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ing Caco-2 cells was inhibited by a COX-2 selective inhibitor,
NS-398, in a dose-dependent manner [60].
COX-2 inhibitors have already been reported to inhibit angio-
genesis, and our study shows for the first time that COX-2 reg-
ulates vascular channel formation in human breast cancer
cells. The mechanism of action of celecoxib in inhibiting chan-
nel formation is not known. Our data suggest that treatment
with celecoxib caused a dose-dependent downregulation of
VEGF in the MDA-MB-231 cells but not in the MDA-MB-468
cells (Fig. 6b). Although additional mechanisms are involved in
mediating the angiogenic effects of COX-2, our data imply that
COX-2 inhibitors influence angiogenesis at least in part by
decreasing the release of VEGF. It was recently reported that
COX-2 induced PGE2 stimulated the expression of angiogenic
regulatory genes, including VEGF, in mammary tumor cells iso-
lated from COX-2 transgenic mice, and that treatment with
indomethacin (a nonspecific COX inhibitor) suppressed the
expression of these genes in vitro [36]. To confirm the in vitro
data, the antiangiogenic effects of celecoxib were evaluated in
an in vivo xenograft model using MDA-MB-231 cell containing
Matrigel implants. Results showed that celecoxib dramatically
reduced the vascularity within the tumor tissue (Fig. 8). In addi-
tion, the treatment caused increased necrosis and reduced
viable tissue mass within the tumor (Figs 7 and 8). Therefore,
the reduced tumor burden in the treated mice can be
explained in part by the inhibition of angiogenesis and confirms
our in vitro data. Previous studies have reported similar effects
of COX-2 inhibitors in an in vivo angiogenesis assay using the
highly metastatic murine mammary tumor cell line C3L5 [45].
Additional studies are needed to fully elucidate the complex
events involved in COX-2 mediated angiogenesis in human
mammary tumors.
To our knowledge, this is the first study to identify some key
mechanisms of action of celecoxib in vitro and in vivo in human
breast cancer cells. More cell lines must be evaluated to char-
acterize fully the antitumor actions of celecoxib, including iden-
tification of its primary targets, the precise molecular
mechanism of cell damage, and the basis for its preferential
effect on tumor cells. Although COX-2 inhibitor treatment
alone is unlikely to eliminate an existing tumor, it is likely that it
can confer significant benefit as part of a carefully chosen reg-
imen involving other drugs. The strategy to target multiple
pathways simultaneously may be critical to improving the effi-
cacy of therapy in the treatment of breast cancer, especially for
metastatic breast cancer. Moore and coworkers [61] reported
that celecoxib, in combination with 5-fluorouracil or cyclophos-
phamide, greatly enhanced the antitumor effects of
chemotherapy in a colon cancer model. In another tumor
model, COX-2 selective inhibitors showed promise in combi-
nation with radiation therapy, enhancing tumor radiation
responses [62]. Celecoxib was recently shown to have chem-
opreventive effects against the development of chemically
induced mammary tumors in the rat [12]. Finally, recent evi-
dence that combined treatment with a nonselective NSAID
and EGFR tyrosine kinase inhibitor significantly decreased
polyp formation in Min APC+/- mice supports the notion that
combination therapy may be more effective [63]. These stud-
ies, combined with the present study and the reports of aber-
rant COX-2 expression in human breast cancer [9,64],
suggest that selective COX-2 inhibitors have an important role
to play in chemoprevention, chemo-intervention, and therapy
of human breast cancer.
Conclusion
We showed that the mechanisms driving celecoxib-induced
growth inhibition of human breast cancer cells are dependent
upon COX-2 expression levels, invasive properties, and
dependence on PGE2. At the cellular level, celecoxib induced
apoptosis in highly invasive cells, but it caused cell cycle arrest
at the G0/G1 phase of the cell cycle without causing apoptosis
in the less invasive cells. At the molecular level, pAkt was
inactivated with increased activation of proapoptotic protein
Bax and caspases 3 and 7. Furthermore, we showed for the
first time that celecoxib inhibited microvascular channel forma-
tion in a dose-dependent manner, associated with downregu-
lation of VEGF in the highly invasive cells. An in vivo xenograft
model confirmed the in vitro data and showed dramatic reduc-
tion in tumor mass accompanied by reduced vascularity and
increased necrosis within the tumor, suggesting that the
reduced tumor burden in the treated mice may in part be due
to reduced angiogenesis.
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